Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1942 1
1962 1
1976 1
1977 2
1979 3
1980 1
1982 2
1983 2
1984 2
1986 3
1987 3
1988 6
1989 11
1990 10
1991 14
1992 8
1993 19
1994 19
1995 15
1996 23
1997 20
1998 15
1999 23
2000 23
2001 24
2002 54
2003 60
2004 57
2005 42
2006 45
2007 55
2008 49
2009 47
2010 45
2011 40
2012 35
2013 44
2014 43
2015 38
2016 33
2017 27
2018 28
2019 23
2020 24
2021 35
2022 29
2023 13
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 12621016

1,029 results

Results by year

Filters applied: . Clear all
Page 1
Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, Raubitschek A, Karvelis K, Schultheiss T, Witzig TE, Belanger R, Spies S, Silverman DH, Berlfein JR, Ding E, Grillo-López AJ. Wiseman GA, et al. Eur J Nucl Med. 2000 Jul;27(7):766-77. doi: 10.1007/s002590000276. Eur J Nucl Med. 2000. PMID: 10952488 Clinical Trial.
A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
Cooney-Qualter E, Krailo M, Angiolillo A, Fawwaz RA, Wiseman G, Harrison L, Kohl V, Adamson PC, Ayello J, vande Ven C, Perkins SL, Cairo MS; Children's Oncology Group. Cooney-Qualter E, et al. Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5652s-5660s. doi: 10.1158/1078-0432.CCR-07-1060. Clin Cancer Res. 2007. PMID: 17875803 Clinical Trial.
Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica D, Bartlett NL, Parker JA, Dunn WL, Spies SM, Belanger R, Witzig TE, Leigh BR. Wiseman GA, et al. Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):181-94. doi: 10.1016/s1040-8428(01)00107-x. Crit Rev Oncol Hematol. 2001. PMID: 11418315 Clinical Trial.
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA. Witzig TE, et al. J Clin Oncol. 2002 May 15;20(10):2453-63. doi: 10.1200/JCO.2002.11.076. J Clin Oncol. 2002. PMID: 12011122 Clinical Trial.
Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.
Wiseman GA, Leigh BR, Erwin WD, Sparks RB, Podoloff DA, Schilder RJ, Bartlett NL, Spies SM, Grillo-López AJ, Witzig TE, White CA. Wiseman GA, et al. Cancer Biother Radiopharm. 2003 Apr;18(2):165-78. doi: 10.1089/108497803765036337. Cancer Biother Radiopharm. 2003. PMID: 12804042 Clinical Trial.
Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels.
Wahl RL, Frey EC, Jacene HA, Kahl BS, Piantadosi S, Bianco JA, Hammes RJ, Jung M, Kasecamp W, He B, Sgouros G, Flinn IW, Swinnen LJ. Wahl RL, et al. Cancers (Basel). 2021 Jun 6;13(11):2828. doi: 10.3390/cancers13112828. Cancers (Basel). 2021. PMID: 34204102 Free PMC article.
1,029 results